Management strategies of academic pigmented lesion clinic directors in the United States - 16/07/18
Doi : 10.1016/j.jaad.2017.12.069
Kelly C. Nelson, MD a, Douglas Grossman, MD, PhD b, Caroline C. Kim, MD c, Suephy C. Chen, MD, MS d, e, Clara N. Curiel-Lewandrowski, MD f, James M. Grichnik, MD, PhD g, John M. Kirkwood, MD h, Sancy A. Leachman, MD, PhD i, Ashfaq A. Marghoob, MD j, Susan M. Swetter, MD k, l, m, Suraj S. Venna, MD n, Michael E. Ming, MD, MSCE o, ⁎ 
a Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas
b Department of Dermatology, University of Utah Health Sciences Center, Salt Lake City, Utah
c Department of Dermatology, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts
d Department of Dermatology, Emory University, Atlanta, Georgia
e Division of Dermatology, Atlanta Veterans Affairs Medical Center, Decatur, Georgia
f University of Arizona Cancer Center, Tucson, Arizona
g Scully-Welsh Cancer Center, Indian River Medical Center, Vero Beach, Florida
h University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
i Department of Dermatology, Oregon Health Sciences University, Portland, Oregon
j Dermatology Service, Memorial Sloan Kettering Skin Cancer Center, Hauppage, New York
k Department of Dermatology, Pigmented Lesion and Melanoma Program, Stanford University Medical Center, Stanford, California
l Cancer Institute, Stanford, California
m Dermatology Service, Veterans Affairs Palo Alto Health Care System, Palo Alto, California
n Inova Schar Cancer Institute, Department of Medicine, Virginia Commonwealth University, Fairfax, Virginia
o Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania
∗Reprint requests: Michael E. Ming, MD, MSCE, Department of Dermatology, University of Pennsylvania School of Medicine, 3600 Spruce St, 2 Maloney Building, University of Pennsylvania Health System, Philadelphia, PA 19104Department of DermatologyUniversity of Pennsylvania School of Medicine3600 Spruce St2 Maloney BuildingUniversity of Pennsylvania Health SystemPhiladelphiaPA19104
| Funding sources: None. |
|
| Conflicts of interest: Dr Kirkwood has been a consultant for Roche, BMS, Novartis, Genentech, EMD Serono, Merck, and Array Biopharma. Dr Kirkwood has also received research grant funding from Prometheus and Merck. Dr Leachman is an advisory board member for Myriad Genetics and Castle Biosciences and is a member of the Early Access Program for Myriad Genetics and Castle Biosciences. All other authors have no conflicts of interest. |
© 2018
American Academy of Dermatology, Inc. Tous droits réservés.
Vol 79 - N° 2
P. 367-369 - août 2018 Retour au numéro
Article précédent
- Efficacy of NB-UVB, microneedling with triamcinolone acetonide, and a combination of both modalities in the treatment of vitiligo: A comparative study
- Shrook Abd Elshafy Khashaba, Reham A. Elkot, Alshimaa M. Ibrahim
- The Vitiligo Extent Score (VES) and the VESplus are responsive instruments to assess global and regional treatment response in patients with vitiligo
- Nanja van Geel, Marcel Bekkenk, Janny E. Lommerts, Khaled Ezzedine, John Harris, Iltefat Hamzavi, Viktoria Eleftheriadou, Mauro Picardo, Alain Taieb, Cecilia A.C. Prinsen, Albert Wolkerstorfer, Reinhart Speeckaert
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?